8-K - ANGO - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-50761	11-3146460
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
14 Plaza Drive, Latham, New York	12110
---	---
(Address of Principal Executive Offices)	(Zip Code)
(518) 795-1400
---
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
---	---
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which<br><br> <br>registered
Common Stock, par value $0.01 per share	ANGO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 –	Submission of Matters to a Vote of Security Holders.
(a)	The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on November 10, 2025.
---	---
(b)	Shareholders of AngioDynamics voted on the matters set forth below.
---	---
1.	The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2028 Annual Meeting of<br> Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:
---	---
Nominee	Votes For	Withheld	Broker Non-Votes
---	---	---	---
James C. Clemmer	29,634,152	800,454	5,462,943
Michael E. Tarnoff, MD	29,245,896	1,188,710	5,462,943
2.	The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the<br> fiscal year ending May 31, 2026 was approved based upon the following votes:
---	---
Votes for approval	35,727,186
---	---
Votes against	156,899
Abstentions	13,464

There were no broker non-votes for this item.

3.	The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon<br> the following votes:
Votes for approval	28,357,782
---	---
Votes against	2,057,982
Abstentions	18,842
Broker non-votes	5,462,943
(c)	Not applicable.
---	---
(d)	Not applicable.
---	---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANGIODYNAMICS, INC.
	(Registrant)
Date: November 12, 2025	By:	/s/ Lawrence T. Weiss
		Name: Lawrence T. Weiss
		Title: Senior Vice President, Chief Legal Officer and Corporate Secretary